EUCTR2016-004744-11-NL进行中（未招募）1 期
PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT) - PERFECT
Academic Medical Center0 个研究点开始时间: 2017年2月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically proven adenocarcinoma of the esophagus or gastro esophageal junc
- •2. The tumor is surgically resectable
- •3. Patient is fit for surgery
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer
研究者
相似试验
招募中
2 期
PDL-1 targeting in resectable oesophageal cancer: a phase II feasibility study of Atezolizumab and chemoradiation (PERFECT)Esophageal cancerNL-OMON55613Academisch Medisch Centrum40
已完成
2 期
PDL-1 Targeting in Resectable Oesophageal CancerEsophageal Cancer, Stage IIEsophageal Cancer Stage IIINCT03087864Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)40
进行中（未招募）
不适用
Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study - Feasibility trial of chemoradiation or surgery for oesophageal canceroesophageal cancerMedDRA version: 12Level: LLTClassification code 10030151Term: Oesophageal cancerEUCTR2009-013877-16-GBniversity Hospitals Bristol NHS Foundation Trust
已完成
2 期
Targeting esophageal cancer with HDL nanoparticles: an imaging study<br>gullet cancer10017991esophageal cancerNL-OMON45362Academisch Medisch Centrum9
进行中（未招募）
1 期
Targeting esophageal cancer with HDL nanoparticles: an imaging studyPrimary esophageal cancerEUCTR2017-000724-10-NLAcademic Medical Center13